Cellectar Enrolls First Patient in CLR 125 Auger-Emitting Radioconjugate Phase 1b Clinical Trial Targeting Refractory Triple Negative Breast Cancer (TNBC)
Clinical Trial Opportunity for Triple-Negative Breast Cancer
Our Science
Our unique, cutting-edge tumor-targeting technology provides optionality to selectively deliver a broad array of therapeutic modalities, including radioisotopes, small molecule cytotoxins and biologics to tumor cells by targeting lipid rafts in the plasma membranes of cancer cells. This may result in maximum antitumor activity with minimal off-target effects.
Lead Candidate:
Iopofosine I 131
Iopofosine is a first-in-class Phospholipid Drug Conjugate (PDC)™ designed to provide targeted delivery of iodine-131 directly to cancer cells while limiting exposure to healthy cells.
Learn More About Iopofosine